ArticleDiscover oncology2026
Comparative study on the functions of LDHA and LDHC in triple-negative breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLactate dehydrogenase (LDH) is a key enzyme in the aerobic glycolysis pathway (Warburg effect) of tumors. Triple-negative breast cancer (TNBC), a subtype of breast cancer, is characterized by elevated levels of the LDHA isoenzyme. However, related research is limited, and whether the functions of LDH isoenzymes differ in TNBC remains unclear. Therefore, this study aimed to investigate the functional similarities and differences between LDHA and LDHC in TNBC progression.
methodsThis study first analyzed the expression levels of LDHA and LDHC in the TCGA-BRCA database via bioinformatics. Lentiviral vectors were used to overexpress or knock down LDHA and LDHC expression. Their effects on TNBC cell proliferation, migration, invasion, and cell cycle were assessed using colony formation assays, MTT assays, Transwell assays, wound healing assays, and flow cytometry. A mouse xenograft tumor model was established to investigate the impact of LDHA and LDHC on TNBC progression in vivo. Western blotting was used to detect changes in key proteins of the PI3K/AKT/mTOR signaling pathway and epithelial-mesenchymal transition (EMT) to preliminarily reveal the underlying mechanisms.
resultsAnalysis of the TCGA-BRCA database showed upregulated expression of both LDHA and LDHC in TNBC samples. In vitro experiments demonstrated that overexpression of either LDHA or LDHC promoted the proliferation, invasion, and migration of MDA-MB-231 cells, with the promoting effect of LDHC being significantly stronger than that of LDHA. Knockdown of LDHA or LDHC inhibited the proliferation, invasion, and migration of MDA-MB-231 cells, and the inhibitory effect of LDHC knockdown on cell proliferation and invasion was stronger than that of LDHA knockdown. Intriguingly, knockdown of LDHC, but not LDHA, induced G1 phase arrest in MDA-MB-231 cells. In vivo experiments showed that overexpression of both LDHA and LDHC promoted the growth of subcutaneous xenograft tumors in mice, with the effect of LDHC being significantly stronger than that of LDHA. Western blot results indicated that overexpression of LDHA and LDHC significantly increased PI3K protein levels and elevated the p-AKT/AKT and p-mTOR/mTOR ratios, whereas their knockdown produced the opposite results. Furthermore, overexpression of LDHA and LDHC led to downregulation of E-cadherin and upregulation of N-cadherin and other related proteins, while knockdown of LDHA and LDHC resulted in the opposite effects.
conclusionOverexpression of both LDHA and LDHC promotes the proliferation, invasion, and migration of MDA-MB-231 cells, with the effect of LDHC overexpression being more pronounced than that of LDHA. Both LDHA and LDHC can regulate the PI3K/AKT/mTOR signaling pathway and the EMT process, which may represent their molecular mechanisms in promoting cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.